ESCALATE Emerging and current landscape in treatment of EGFRm NSCLC

The Emerging Landscape of Immunotherapy in NSCLCПодробнее

Current Treatment Landscape for NSCLCПодробнее

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLCПодробнее

Current treatment recommendations and future directions for EGFR-mutant NSCLCПодробнее

EGFR TKIs Excite Treatment Landscape of EGFR-Mutant Lung CancersПодробнее

The Changing Landscape of First Line Treatment for EGFR Mutation-Positive NSCLC.Подробнее

Therapy sequencing in the current NSCLC treatment landscapeПодробнее

Emerging treatment strategies in EGFR-mutant NSCLC: osimertinib combinations and beyondПодробнее

Treatment for Patients with EGFR+ NSCLC - Leading Developments & Current Questions in Lung CancerПодробнее

Emerging Data in EGFR-Mutant Lung CancerПодробнее

Changing Landscape of EGFR+ mNSCLCПодробнее

Segment 1: EGFR TKIs in NSCLCПодробнее

2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2Подробнее

ILCN Multidisciplinary Forum: Understanding Treatment Options and Resistance in EGFR-positive NSCLCПодробнее

Emerging Role of EGFR-Targeted Therapy in Resectable Lung CancerПодробнее

The evolving treatment landscape for NSCLC with EGFR exon 20 insertion mutationsПодробнее

Keynote Lecture: Targeted Therapies in Lung Cancer 2.0 – Advances and PromisesПодробнее

Emerging Options for Treatment of EGFR-Positive NSCLCПодробнее